Table 6.
Relationship between expression of IDO1, FASLG and NT5E and clinical parameters in CCA patients.
| Clinical Attribute | p = 1.874 × 10−3 | p = 0.937 | p = 0.969 | |||
|---|---|---|---|---|---|---|
| Neoplasm disease stage American Joint Committee on Cancer Code | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| Stage I | 0% | 55.88% | 20% | 58.06% | 100% | 51.43% |
| Stage II | 50% | 23.53% | 60% | 19.35% | 0% | 25.71% |
| Stage III | 50% | 0% | 0% | 3.23% | 0% | 2.86% |
| Stage IV | 0% | 5.88% | 0% | 6.45% | 0% | 5.71% |
| Stage IVA | 0% | 5.88% | 20% | 3.23% | 0% | 5.71% |
| Stage IVB | 0% | 8.82% | 0% | 9.68% | 0% | 8.57% |
| p = 0.739 | p = 0.018 | p = 3.492 × 10−3 | ||||
| Metastasis stage American Joint Committee on Cancer Code | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| M0 | 100% | 76.47% | 60% | 80.65% | 0% | 80% |
| M1 | 0% | 14.71% | 0% | 16.13% | 0% | 14.29% |
| MX (No information available) | 0% | 8.82% | 40% | 3.23% | 100% | 5.71% |
| p = 0.665 | p = 0.041 | p = 0.041 | ||||
| Neoplasm disease lymph node stage American Joint Committee on Cancer Code | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| N0 | 0% | 70.59% | 40% | 77.42% | 0% | 74.29% |
| N1 | 74.29% | 14.71% | 20% | 12.9% | 0% | 14.29% |
| NX (No information available) | 14.29% | 14.71% | 40% | 9.68% | 100% | 11.43% |
| p = 0.301 | p = 0.937 | p = 0.922 | ||||
| Tumor stage American Joint Committee on Cancer Code | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| T1 | 0% | 55.88% | 20% | 58.06% | 100% | 51.43% |
| T2 | 50% | 14.71% | 0% | 19.35% | 0% | 17.14% |
| T2a | 0% | 5.88% | 40% | 0% | 0% | 5.71% |
| T2b | 0% | 11.76% | 40% | 6.45% | 0% | 11.43% |
| T3 | 50% | 11.76% | 0% | 16.13% | 0% | 14.29% |
| p = 0.049 | p = 1.046 × 10−3 | p = 3.565 × 10−3 | ||||
| Neoadjuvant therapy type administered prior to resection | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| YES | 0% | 2.94% | 0% | 2.86% | 0% | 2.86% |
| NO | 100% | 97.06% | 100% | 97.14% | 100% | 97.14% |
| p = 0.012 | p = 1.00 | p = 0.998 | ||||
| History hepatocellular risk factor | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | Altered NT5E | Unaltered |
| Hepatitis B and smoking | 50% | 0% | 60% | 6.67% | 0% | 26.47% |
| No history of primary risk factors | 50% | 58.82% | 20% | 63.33% | 100% | 55.88% |
| Other risk factors (cirrhosis/diabetes mellitus/NAFLD/ smoking/ulcerative colitis) | 0% | 41.1% | 20% | 30% | 0% | 17.65% |
| p = 0.569 | p = 0.910 | p = 0.930 | ||||
| Gender | Altered IDO1 | Unaltered | Altered FASLG | Unaltered | AlteredNT5E | Unaltered |
| Male | 50% | 44.12% | 40% | 45.16% | 100% | 44.12% |
| Female | 50% | 55.88% | 60% | 54.84% | 0% | 55.88% |